



**Genetic Epidemiology of Prostate Cancer in Africa
Medical Record Abstraction-Cases**

1. Participant ID: - - -

2. Medical Record#: _____

3. Abstractor Initials: 4. Abstraction Date: ___/___/_____
(Month/Day/Year)

5. Prostate Cancer Diagnosis Date: ___/___/_____
(Month/Day/Year)

6. DRE at Prostate cancer diagnosis Date: ___/___/_____
(Month/Day/Year)

- Normal
- Abnormal/suspicious
- Unknown

7. PSA at Prostate cancer diagnosis

- Normal
- Abnormal/suspicious → Specify level ng/ml .
- Unknown

8. Note if Proscar or Propecia* was taken when the PSA at diagnosis was determined?

- Yes → Duration _____ (years/months) Frequency _____ (pills/day)
- No
- Unknown

9. Number of biopsies prior to Prostate Cancer diagnosis

Date(s): ___/___/____ _ ___/___/____ _ ___/___/_____
(Month/Day/Year) (Month/Day/Year) (Month/Day/Year)

10. Number of TURPS prior to Prostate Cancer diagnosis


Date(s): ___/___/____ _ ___/___/____ _ ___/___/_____
(Month/Day/Year) (Month/Day/Year) (Month/Day/Year)

11. Path Confirmation of Tumor

- Yes
- No
- Unknown

12. Location of Tumor

Using the image below, check the corresponding box indicating the zone the tumor (or was originally) located:



- Central Zone
- Transitional Zone
- Peripheral Zone
- Multiple
- Unknown: _____

13. Gleason Grade/Score (biopsy, TURP)

+ =

14. Gleason Grade/Score (prostatectomy)

+ =

15. Clinical Summary Stage

Primary Tumor (T)

- TX** Primary tumor cannot be accessed
- T0** No evidence of primary tumor
- T1** Clinically inapparent tumor neither palpable nor visible by imaging
- T1a** Tumor incidental histologic finding in $\leq 5\%$ of resected tissue
- T1b** Tumor incidental histologic finding in $>5\%$ of resected tissue
- T1c** Tumor identified by needle biopsy (eg, because of elevated PSA level)
- T2** Tumor confined within prostate
- T2a** Tumor involves one-half of one lobe or less
- T2b** Tumor involves more than one-half of one lobe but not both lobes
- T2c** Tumor involves both lobes
- T3a** Extracapsular extension (unilateral or bilateral)
- T3b** Tumor invades seminal vesicle(s)
- T4** Bladder invasion, fixed to pelvic side wall, or invasion of adjacent structures
- Unknown**

Describe: _____

16. Surgical Pathology Tumor Stage (TNM):

Primary Tumor (T)

- TX** Primary tumor cannot be accessed
- T0** No evidence of primary tumor
- T1** Clinically inapparent tumor neither palpable nor visible by imaging
- T1a** Tumor incidental histologic finding in $\leq 5\%$ of resected tissue
- T1b** Tumor incidental histologic finding in $>5\%$ of resected tissue
- T1c** Tumor identified by needle biopsy (eg, because of elevated PSA level)
- T2** Tumor confined within prostate
- T2a** Tumor involves one-half of one lobe or less
- T2b** Tumor involves more than one-half of one lobe but not both lobes
- T2c** Tumor involves both lobes
- T3a** Extracapsular extension (unilateral or bilateral)
- T3b** Tumor invades seminal vesicle(s)
- T4** Bladder invasion, fixed to pelvic side wall, or invasion of adjacent structures
- Unknown**

Describe: _____

Regional Lymph Nodes (N)

- T3a** Regional lymph nodes cannot be assessed
- T3b** No regional lymph node metastasis
- T4** Metastasis to regional lymph nodes
- Unknown**

Describe: _____

Distant Metastasis (M)

- MX** Presence of distal metastasis cannot be assessed
- M0** No distant metastasis
- M1** Distant metastasis
- M1a** Metastasis to non-regional lymph nodes
- M1b** Metastasis to bone
- M1c** Metastasis to other distant sites
- Unknown**

Describe: _____

17. Imaging undertaken (check all that apply):

Type of Imaging	✓	Description/Dates (Month/Day/Year)
CT Scan		
MRI		
X-Ray		
Ultrasound		
Bone Scan		

18. Please describe how staging was determined: _____

19. Treatment (check all applicable)

TREATMENT	✓	DATE/S (Month/Day/Year)	Further details on treatment protocol
Radical/partial Prostatectomy			
Androgen Therapies			
1) Orchiectomy			
2) LHRH Agonists/Antagonists Leuprolide (Lupron, Eligard) Goserelin (Zoladex) Triptorelin (Trelstar) Histrelin (Vantas) Degarelix (Firmagon)			
3) Anti-Androgens Flutamide (Eulexin) Bicalutamide (Casodex) Nilutamide (Niladron)			
4) Androgen inhibitors Abiraterone (Zytiga) Enzalutamide (Xtandi)			
5) Estrogen			
Brachytherapy (Seeds)			
Cryosurgery			
Chemotherapy Docetaxel (Taxotere) Cabazitaxel (Jevtana) Mitoxantrone (Novantrone) Estramustine (Emcyt)			
X-Beam Treatment/Radiation			
Proton Therapy			
Active Surveillance/Watchful waiting			
Other Treatment			
Unknown or not specified			

If selected Other treatment describe: _____

20. Tumor Present at Resection Margins:

- No
- Yes
- Unknown/Not specified

21. Did Post-Treatment Failure occur?

- Yes

If yes, was it due to:

- Elevated PSA
- Positive Biopsy of Prostate
- Metastasis to structure/s adjacent to prostate
- Metastasis to pelvic lymph node
- Distant metastasis (bone, non-regional lymph node)

- No
- Not applicable

If Not applicable, is this because:

- Patient is still undergoing treatment (or in the Casodex study) & no indication of an elevated PSA exists (i.e. PSA has not been tested, or PSA remains low)
- Patient has not received any treatment
- Patient's PSA has not been tested since the completion of treatment
- Metastasis to pelvic lymph node
- Less than (or equal to) 12 months have passed since seeds were implanted

- No
- Unknown

22. PSA other recordings– Starting with most recent post-treatment PSA

Date(s) (Month/Day/Year)	PSA Value (ng/ml)	Date(s) (Month/Day/Year)	PSA Value (ng/ml)

23. Did the patient have Benign prostatic hyperplasia (BPH) or chronic prostatitis (CP)?

- No
- Yes-please specify source(s) and description/date(s) of diagnosis

	Source:	Date(s) (Month/Day/Year)	Clinical Notes
<input type="checkbox"/>	Ultrasound		
<input type="checkbox"/>	MRI		
<input type="checkbox"/>	CT Scan		
<input type="checkbox"/>	Path Report		
<input type="checkbox"/>	Clinical Detection		
<input type="checkbox"/>	Pre-op		
<input type="checkbox"/>	Other (cystoscopy, etc)		

24. Co-morbidities:

- No
- Yes (please indicate in chart below):

	Classification:	Date(s) (Month/Day/Year)	If yes, provide details of Medication
<input type="checkbox"/>	Diabetes		
<input type="checkbox"/>	High blood pressure		
<input type="checkbox"/>	High cholesterol		
<input type="checkbox"/>	Heart attack		
<input type="checkbox"/>	Asthma		
<input type="checkbox"/>	Chronic bronchitis		
<input type="checkbox"/>	HIV/AIDS		
<input type="checkbox"/>	Hepatitis		
<input type="checkbox"/>	Malaria		
<input type="checkbox"/>	Cirrhosis		
<input type="checkbox"/>	Ulcers		
<input type="checkbox"/>	Thyroid disease		
<input type="checkbox"/>	Rheumatoid arthritis		
<input type="checkbox"/>	Chronic back pain		
<input type="checkbox"/>	Depression/anxiety		
<input type="checkbox"/>	Urinary tract infection		
<input type="checkbox"/>	Gonorrhea		
<input type="checkbox"/>	Syphilis		
<input type="checkbox"/>	Herpes		
<input type="checkbox"/>	Other		